Corrigendum to “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites”
Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham
{"title":"Corrigendum to “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites”","authors":"Jasmohan S. Bajaj, James H. Fischer, Patrick Yeramian, Edith A. Gavis, Andrew Fagan, Paolo Angeli, Guadalupe Garcia-Tsao, Jonathan M. Adams, Penelope Markham","doi":"10.1155/2023/9815951","DOIUrl":null,"url":null,"abstract":"<p>In the article titled “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites” [<span>1</span>], there was an error in the Conflicts of Interest section, where Jasmohan S. Bajaj was incorrectly listed as an employee of BioVie, Inc. Additionally, some additional information was omitted in error. The corrected section appears in the following:</p><p>JF and PY are consultants who received compensation from BioVie. EG and AF received none. PA is a clinical advisor who received honorarium from BioVie and from Grifols. GG-T is a clinical advisor who received honorarium from BioVie. JSB received grant support to his institution from BioVie. JA and PM are BioVie employees.</p>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"2023 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9815951","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2023/9815951","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In the article titled “Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites” [1], there was an error in the Conflicts of Interest section, where Jasmohan S. Bajaj was incorrectly listed as an employee of BioVie, Inc. Additionally, some additional information was omitted in error. The corrected section appears in the following:
JF and PY are consultants who received compensation from BioVie. EG and AF received none. PA is a clinical advisor who received honorarium from BioVie and from Grifols. GG-T is a clinical advisor who received honorarium from BioVie. JSB received grant support to his institution from BioVie. JA and PM are BioVie employees.
在题为“肝硬化和难治性腹水患者持续静脉输注特立普利辛的安全性、耐受性、药代动力学和疗效”的文章中，在利益冲突部分有一个错误，Jasmohan S. Bajaj被错误地列为BioVie， Inc.的员工。此外，错误地遗漏了一些附加信息。更正后的部分如下：JF和PY是获得BioVie报酬的顾问。EG和AF则没有。PA是一位从BioVie和Grifols获得酬金的临床顾问。GG-T是一名从BioVie获得酬金的临床顾问。JSB的机构获得了BioVie的资助。JA和PM都是BioVie的员工。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
